Legislation
The ORPHAN Cures Act: Bipartisan, Bicameral Legislation
Legislation Restores Incentives for Research & Development of Rare Disease Treatments
Polling
The Biotechnology Innovation Organization released a poll indicating strong voter support for the ORPHAN Cures Act, which aims to incentivize the development of drugs for rare diseases by addressing issues in the Inflation Reduction Act. The survey found that 94% of American voters prioritize research for rare disease treatments, and nearly 70% would support their representatives voting for the bill. Currently, 95% of rare diseases lack FDA-approved treatments, highlighting the urgent need for legislative action. Click here to read the press release.
Click here to view the full results of the poll.
Related Materials
- Biotechnology Industry Organization: ORPHAN Cures Act One-Pager
- Biotechnology Industry Organization: ORPHAN Cures Act a “welcome and bipartisan fix” to the IRA’s negative impact on drug development
- California Life Sciences: California Life Sciences Urges Congress to Support Rare Disease Patients
- Rare Disease Company Coalition: New Bill Protects Continued Development for Rare Disease Medicines